Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Imiquimod for Persistent High-Risk HPV After Cervical Cancer Treatment
2010-019657-18Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Apr 2010
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in human papillomavirus infection and Cervical Cancer (CC) comparing Imiquimod arm with Observation arm (2 arms). Primary endpoint: High-risk HPV clearance at 20 weeks. Started Apr 2010; status: terminated.
02
Drugs
imiquimod
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on 2010-019657-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019657-18.